Brief Communication

The streptozotocin-high fat diet induced diabetic mouse model exhibits severe skin damage and alterations in local lipid mediators

Alberto Leguina-Ruzzi\textsuperscript{a,}\textsuperscript{*}, Rina Ortiz\textsuperscript{b}, Victoria Velarde\textsuperscript{c}

\textsuperscript{a} School of Medicine, Juntendo University, Tokyo, Japan
\textsuperscript{b} Biotechnology Center, Federico Santa Maria Technical University and Faculty of Health, Department of Chemical and Biological Sciences, Bernardo O’Higgins University, Santiago, Chile
\textsuperscript{c} Faculty of Biological Sciences, Department of Physiology, Pontifical Catholic University of Chile, Santiago, Chile

\textbf{Article info}

\textbf{Article history:}
Received 23 December 2017
Accepted 6 August 2018
Available online 3 November 2018

\textbf{Keywords:}
Diabetes
Streptozotocin
Lipid mediators
Skin damage
Epithelial integrity

\textbf{Abstract}

Background: Type 2 diabetes (T2D) can go undiagnosed for years, leading to a stage where produces complications such as delayed skin wound healing. Animal models have been developed in the last decades to study the pathological progression in this disease. Streptozotocin (STZ), that has a selective pharmacological toxicity toward pancreatic \( \beta \) cells, in addition to high fat diet has been widely used to induce diabetes however no evidence has shown its effects on the skin integrity.

Methods: Eighteen C57BL/6J male mice, were divided in 3 groups; the first was fed with chow diet and the second was kept on a high fat diet and the third injected with STZ intraperitoneal for 5 days consecutively before starting the diet protocol with high fat. Mice were maintained 5 weeks in total.

Results: We show that animals treated with STZ-high fat diet exhibit skin injuries without significant alterations on basal insulin and triglycerides, compared to the control. The skin from these animals presents higher levels of oxidative stress, lower levels of adhesion proteins and alterations in lipid mediators, effects that are not produced by the high fat diet itself.

Conclusion: Our results suggest that this in vivo model represents a relevant approach for studying skin damage induced by diabetes.

Diabetes affects over 340 million people worldwide. It is characterized by sustained hyperglycemia and can go undiagnosed for years \[1\]. Its chronicity leads to delayed wound healing due to skin complications increasing the risk of amputation; the foot ulcer is a leading cause of hospital admissions in the developed world and is a major morbidity associated with diabetes, often leading to pain, suffering, and a poor quality of life \[2\].

\* Corresponding author. School of Medicine, Juntendo University, Tokyo, Japan.
E-mail address: albertoandres.leguinaruzzi@fgu.cas.cz (A. Leguina-Ruzzi).

\[1\] Present address: v.v.l. Department of Mitochondrial Physiology, Institute of Physiology AS CR, Vídeňská 1083, 14220 Prague 4, Czech Republic.

https://doi.org/10.1016/j.bj.2018.08.005
2319-4170/© 2018 Chang Gung University. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
The oxidative stress and lipids content has been considered as the mechanism underlying the abrogated skin integrity [3]. However, there is no report showing the local alterations in the skin of diabetic animal models.

Several non-genetic mice models have been established. The most widely used are based on high fat (HF) diet with or without a chemical ablation of the pancreatic β cells using streptozotocin (STZ) [4]. Nevertheless, no characterization of the skin alterations on the models have been reported [5].

We used two diabetic-induced mice models to study the skin condition in addition to the oxidative stress and local levels of lipid mediators that might contribute to the skin disruption.

Materials and methods

Eighteen C57BL/6J male mice of 15–21 weeks of age (average weight 23 ± 0.5 g), were divided in 3 groups. The first group was fed with a low fat Chow D1245B as a control, the second was kept on a HF diet D12492. The content in fat percentage of the diets are 10% kcal% fat and 60% kcal% fat, respectively. The third was injected with STZ (40 mg/kg) (Cayman Chemicals, catalog no. 18883664) intraperitoneal (IP) for 5 days consecutively before starting the diet protocol with HF. The compound was dissolved in 0.05 M citrate buffer, pH 4. In parallel the control and HF groups were injected with the vehicle during the pretreatment. Mice were maintained 5 weeks in total, since STZ or vehicle treatment.

Parameters were controlled weekly after 6 h of fasting. The study protocol was approved by the Ethics Committee for Animal Experimentation at Juntendo University, Japan.

Triglycerides and blood glucose levels were measured using CardioChek® PA (catalog no. 0197) and the compatible PTS Panel® test strips. Insulin was measured using the Ultra-sensitive Mouse ELISA kit (Mercodia, article no. 10-1249-01).

Ex vivo trans-epithelial electrical resistance (TEER) measurement was performed in skin samples with an 8 mm diameter and 1 mm thickness obtained from the back of the animal using disposable biopsy punches (Kai Medical, catalog no. BP-80F). Samples were placed facing up onto a 12 mm animal using disposable biopsy punches (Kai Medical, catalog no. BP-80F). Samples were taken using Keyence BZ-9000 microscope. Western blot used anti-ZO-1 pAb (Thermo Fisher Scientific-Invitrogen catalog no. MERS00002).

Oxidative stress was measured using TBARS assay Kit (Cayman Chemicals, catalog no. 10009055).

Histological analysis was performed in skin samples fixed with 10% formalin, paraffin-embedded, and stained with hematoxylin eosin (HE) and masson’s trichrome (MT). Images were taken using Keyence BZ-9000 microscope.

Results

Mice fed with HF diet showed a higher weight gain (p < 0.001) from the second week onwards. The animals pretreated with STZ (Type 2 diabetes (T2D) mice) exhibited an early weight loss followed to a normalization towards values similar to control [Fig. 1A]. The HF diet induced higher glucose basal levels, effect that was enhanced by the STZ from the third week [Fig. 1B]. Moreover, the STZ treatment did not alter the triglycerides and insulin basal levels (p = 0.1), parameters affected by the HF diet [Fig. 1C and D; respectively].

The skin from diabetic mice exhibited lower TEER (p < 0.05) than control, effect that is potentiated by STZ (*p < 0.01) [Fig. 1E, grey bar and black bar; respectively]. However, the levels of TBARS were significantly higher only in the skin from the HF + STZ animals (p < 0.05) [Fig. 1F, black bar]. The macroscopic view showed severe spontaneous skin lesions on animals pretreated with STZ and histological sections suggested an atrophic epidermis without signs of inflammatory cell infiltration or vasculitis with a reduction of hair follicles [Fig. 1G]. Consistent with the observations, the skin from mice under HF and STZ showed lower adhesion protein levels of ZO-1, E-Cadherin, Occludin and Claudin-4 [Fig. 1H].

In addition, the skin from STZ-HF mice showed lower levels of lipid mediators docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), 12-hydroxyeptadecatrienoic acid (HETE), with ImageJ software (National Institutes of Health).

For the determination of lipid content, it was performed an extraction from skin with methanol containing deuterium-labeled internal standards. Each sample was diluted with water to yield a final methanol concentration of 20%, and then loaded on Oasis HLB cartridges (Waters). The column was subsequently washed with petroleum ether and water containing 0.1% formic acid. The samples were eluted with 200 μl of methanol containing 0.1% formic acid. Eicosanoids in each sample were quantified by LC-MS/MS using a Shimadzu liquid chromatography system and tandem-connected a TSQ Quantum Ultra triple quadrupole mass spectrometer equipped with an electrospray ionization system (Thermo Fisher Scientific). Each sample was injected into the trap column, an Opti-Guard Mini C18 and concentrated sample was analyzed with an analytical column, a Capcell Pak C18 MGS3 (Shiseido, Tokyo, Japan). Separation of lipids was achieved by a step gradient with 0.1% formic acid in water and 0.1% formic acid in acetonitrile. The LC column eluent was introduced directly into a TSQ Quantum Ultra. All compounds were analyzed in a negative ion polarity mode.

Results are presented as mean ± SEM. Statistical analyses were performed using ANOVA. Post hoc tests were also performed. Statistical significance was set at p < 0.05. All statistics were calculated using Prism GraphPad (GraphPad Software, Inc., La Jolla, CA, USA).
(HHT), leukotriene C4 (LTC4), protectin D1 (PD1), thromboxane B2 (TXB2), 6-keto-PGF1\(\alpha\), 5-oxoeicosatetraenoic acid (KETE), 12-KETE and 8,9 epoxyeicosatrienoic acids (EET) and higher amount of PGD2, PGE2, 9-hydroxyoctadecadienoic acid (HODE), 13-HODE and 7-hydroxydocosahexaenoic acid (HDoHE), compared to HF and control skin [Table 1].

**Discussion**

Skin changes result from an impaired skin barrier that is caused by either diabetes-induced skin metabolism abnormalities or diabetic complications, such as foot ulcer [6].

Previous results using the HF diet model have described mild skin alterations associated with reduction on TEER, epidermis thickness and increased inflammatory markers [7]. Using a STZ type 1 diabetic rat model it was described in skin an increase on inflammatory cells infiltration and oxidative stress [8]. Moreover, increased TBARS have been reported in the skin of T2D patients [9] and in STZ diabetic rats [10,11].

Furthermore, it was recently described in a type 1 diabetic mice model a disruption on the skin barrier accompanied by disorganization on the tight junctions characterized by a change on ZO-1 protein localization [12]. In agreement with the previously mentioned observations, we show a dramatic reduction in the levels of ZO-1, E-Cadherin, Occludin and Claudin-4 in the STZ-HF T2D model, a condition that may be associated with the reduction on TEER. It is important to highlight that our model would represent T2D in a severe and uncontrolled glycaemia state, as the main trigger of the conditions presented in this study. The severity of the phenotype could be attributed to the synergic effect to the glucose level, that has the high fat diet after the \(b\) cells ablation.

Interestingly, the reduction on skin DHA and EPA has been associated with alteration in the epidermal barrier [13], the decrease in PD1, PGF1\(\alpha\), KETE and EET with inflammation [3,14,15], TXB2 indicating lesions [15] and 12-HHT through BLT2 receptor, has been described as a pro regenerative lipid mediator [16]. On the other hand, the local increase of PGD2, PGE2, and HODEs has been associated with hair loss, inflammation and oxidative stress [17–19].

We identify as weakness of our study the lack of in \(v\)ivo wound healing studies, however the data shown in this study describes a highly used animal model that would serve as evidence for future research in the dermatoendocrinology field.
Conclusion

Animals treated with STZ-high fat diet exhibit skin injuries without significant metabolic alterations, compared to the control. The skin from these animals presents higher levels of oxidative stress, lower levels of adhesion proteins and alterations in lipid mediators, effects that are not produced by the high fat diet itself.

Based on the findings presented in this study and our previous report [7] we suggest that the severe hyperglycemia and no the insulin, in the STZ-high fat diet model, leads to an outburst of pro-inflammatory cytokines and oxidative stress on the keratinocyte, that activates LOX/COX dependent pathways causing changes on local lipid mediators associated with loose on the epidermal integrity that might cause the spontaneous skin injuries observed [20].

The relevance of understanding and characterizing the diverse diabetic animal models represent an important contribution to emulate the pathological condition. The studies on the field are relevant to counteract this important public health issue; and for this reason, the use of proper animal models and more work on this topic is required.

Conflicts of interest

There are no conflicts of interest.

Acknowledgement and funding sources

This work was supported by the Ministry of Education, Culture, Sports, Science and Technology of Japan grant (15H05904, 15H04708, and 18H02627) to the Biochemistry 1 laboratory where this work was executed. ALR was supported as post-doctoral fellow by the Research Institute for Disease of Old Age (2015-2016) having as affiliation Juntendo University, School of Medicine, Tokyo, Japan.

ALR deeply thanks to Dr T. Yokomizo for the mentorship, also the authors thank M. Ohba for the technical support.

Appendix A. Supplementary data

Supplementary data related to this article can be found at https://doi.org/10.1016/j.bj.2018.08.005.

REFERENCES

[1] Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care 2009;32(S 2):S151–6.
[2] Cavanagh P, Attinger C, Abbas Z, Bal A, Rojas N, Xu ZR. Cost of treating diabetic foot ulcers in five different countries. Diabetes Metab Res Rev 2012;28(S 1):107–11.
[3] Stadler R, Schmidt K. Dietary fatty acids and skin diseases. In: Schroder JM, editor. Fatty acids and inflammatory skin diseases. Progress in inflammation research. Basel: Birkhauser; 1999.
[4] Gilbert ER, Fu Z, Liu D. Development of a nongenetic mouse model of type 2 diabetes. Exp Diabetes Res 2011;2011:416254.
[5] King AJ. The use of animal models in diabetes research. Br J Pharmacol 2012;166:877–94.
[6] Armstrong DG, Boullon AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med 2017;376:2367–75.
[7] Leguina-Ruzzi A, Valderas JP. BLT2 expression improves skin integrity and protects from alterations caused by hyperglycemia in type 2 diabetes. Dermatodocrinology 2016;9:e126708.
[8] Andrade TAM, Masson-Meyers DS, Caetano GF, Terra VA, Ovidio PP, Jordao-Juener AA, et al. Skin changes in streptozotocin-induced diabetic rats. Biochem Biophys Res Commun 2017;490:1154–61.
[9] Freitas JP, Filippe P, Guerra Rodrigo F. Glycosylation and lipid peroxidation in skin and in plasma in diabetic patients. C R Seances Soc Biol Fil 1997;191:837–43.
[10] Matsunami T, Sato Y, Sato T, Yukawa M. Antioxidant status during oxygen exposure. Physiol Res 2010;59:97–104.
[11] Gülen S, Dinçer S. Effects of leptin on oxidative stress in healthy and streptozotocin-induced diabetic rats. Mol Cell Biochem 2007;302:59–65.
[12] Okano J, Kojima H, Katagi M, Nakagawa T, Nakae Y, Terashima T, et al. Hyperglycemia induces skin barrier dysfunctions with impairment of epidermal integrity in non-
wounded skin of type 1 diabetic mice. PLoS One 2016;11:e0166215.

[13] Kendall AC, Kiezel-Tsugunova M, Brownbridge LC, Harwood JL, Nicolaou A. Lipid functions in skin: differential effects of n-3 polyunsaturated fatty acids on cutaneous ceramides, in a human skin organ culture model. Biochim Biophys Acta 2017;1859(9 Pt B):1679–89.

[14] Serhan CN, Yacoubian S, Yang R. Anti-inflammatory and proresolving lipid mediators. Annu Rev Pathol 2008;3:279–312.

[15] Andoh T, Yamamoto A, Haza S, Yuhki KI, Ushikubi F, Narumiya S, et al. Thromboxane A2 is involved in itch-associated responses in mice with atopic dermatitis-like skin lesions. Acta Derm Venereol 2016;96:899–904.

[16] Liu M, Saeki K, Matsunobu T, Okuno T, Koga T, Sugimoto Y, et al. 12-Hydroxyheptadecatrienoic acid promotes epidermal wound healing by accelerating keratinocyte migration via the BLT2 receptor. J Exp Med 2014;211:1063–78.

[17] Nakanishi M, Rosenberg DW. Multifaceted roles of PGE2 in inflammation and cancer. Semin Immunopathol 2013;35:123–37.

[18] Barr RM, Koro O, Francis DM, Black AK, Numata T, Greaves MW. The release of prostaglandin D2 from human skin in vivo and in vitro during immediate allergic reactions. Br J Pharmacol 1988;94:773–80.

[19] Hattori T, Obinata H, Ogawa A, Kishi M, Tatei K, Ishikawa O, et al. G2A plays proinflammatory roles in human keratinocytes under oxidative stress as a receptor for 9-hydroxyoctadecadienoic acid. J Invest Dermatol 2008;128:1123–33.

[20] Luo L, Tanaka R, Kanazawa S, Lu F, Hayashi A, Yokomizo T, et al. A synthetic leukotriene B4 receptor type 2 agonist accelerates the cutaneous wound healing process in diabetic rats by indirect stimulation of fibroblasts and direct stimulation of keratinocytes. J Diabet Complicat 2017;31:13–20.